AtonRa Partners’s Legend Biotech LEGN Stock Holding History

AtonRa Partners’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$532K	Sell	8,847 -1,065	-11%	-$67.5K	1.06%	31
2023 Q3	$666K	Sell	9,912 -7,070	-42%	-$491K	1.4%	12
2023 Q2	$1.17M	Sell	16,982 -928	-5%	-$60.6K	1.82%	6
2023 Q1	$864K	Sell	17,910 -2,099	-10%	-$103K	1.26%	15
2022 Q4	$999K	Sell	20,009 -8,141	-29%	-$394K	1.27%	23
2022 Q3	$1.15M	Sell	28,150 -22	-0.1%	-$1.03K	1.13%	31
2022 Q2	$1.55M	Sell	28,172 -22,756	-45%	-$961K	1.42%	10
2022 Q1	$1.85M	Sell	50,928 -11,921	-19%	-$471K	1.01%	38
2021 Q4	$2.93M	Buy	62,849 +29,356	+88%	+$1.49M	1.02%	44
2021 Q3	$1.69M	Buy	+33,493	New	+$1.39M	0.57%	70

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AtonRa Partners's LEGN Position: Q4 2023 in Review

AtonRa Partners reduced its Legend Biotech (LEGN) stake by 11% in Q4 2023, selling an estimated $67.5K and leaving 8,847 shares worth $532K. The position accounts for 1.06% of the portfolio, ranked #31.

AtonRa Partners first reported a position in LEGN in Q3 2021 and has held it in 10 quarters since. The position peaked at $2.93M in Q4 2021. 206 funds tracked by Wall St. Rank hold LEGN as of Q4 2023.

AtonRa Partners held 8,847 shares of Legend Biotech worth $532K as of Q4 2023.
AtonRa Partners sold 1,065 Legend Biotech shares in Q4 2023, an estimated $67.5K.
Legend Biotech made up 1.06% of AtonRa Partners's portfolio in Q4 2023, its #31 holding.
AtonRa Partners first reported a position in Legend Biotech in Q3 2021 and has held it in 10 quarters since.
AtonRa Partners's Legend Biotech position peaked at $2.93M in Q4 2021.
206 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.